Intensity Therapeutics (INTS) Net Equity Issued and Repurchased (2025 - 2026)
Intensity Therapeutics' (INTS) quarterly Net Equity Issued and Repurchased came in at $157000.0 in Q1 2026, down 54.49% YoY from $345000.0 in Q1 2025, and down 95.82% on a QoQ basis from $3.8 million in Q4 2025.
Intensity Therapeutics (INTS) Net Equity Issued and Repurchased (2025 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $157000.0 in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 54.49% year-over-year to $157000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (up 3219.13% YoY) and the FY2025 annual result came in at $11.6 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased eased to $157000.0 in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $7.5 million in Q3 2025 to a low of $157000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | - |
| 10 | Intensity Therapeutics | 12.56 Mn | 12.56 Mn | - | 1.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.66 Mn |
| Jun 30, 2026 | 1.66 Mn |
| Mar 31, 2026 | 157,000.00 |
| Mar 31, 2026 | 157,000.00 |
| Dec 31, 2025 | 3.76 Mn |
| Dec 31, 2025 | 3.76 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Sep 30, 2025 | 7.54 Mn |
| Mar 31, 2025 | 345,000.00 |
| Mar 31, 2025 | 345,000.00 |